» Articles » PMID: 38497810

Effects of Kratom on Driving: Results from a Cross-sectional Survey, Ecological Momentary Assessment, and Pilot Simulated Driving Study

Abstract

Objectives: Despite widespread kratom use, there is a lack of knowledge regarding its effects on driving. We evaluated the self-reported driving behaviors of kratom consumers and assessed their simulated-driving performance after self-administering kratom products.

Methods: We present results from: 1) a remote, national study of US adults who regularly use kratom, and 2) an in-person substudy from which we re-recruited participants. In the national study ( = 357), participants completed a detailed survey and a 15-day ecological momentary assessment (EMA) that monitored naturalistic kratom use. For the remote study, outcomes were self-reported general and risky driving behaviors, perceived impairment, and driving confidence following kratom administration. For the in-person substudy, 10 adults consumed their typical kratom products and their driving performance on a high-fidelity driving simulator pre- and post-kratom administration was evaluated.

Results: Over 90% of participants surveyed self-reported driving under the influence of kratom. Most reported low rates of risky driving behavior and expressed high confidence in their driving ability after taking kratom. This was consistent with EMA findings: participants reported feeling confident in their driving ability and perceived little impairment within 15-180 min after using kratom. In the in-person substudy, there were no significant changes in simulated driving performance after taking kratom.

Conclusions: Using kratom before driving appears routine, however, self-reported and simulated driving findings suggest kratom effects at self-selected doses among regular kratom consumers do not produce significant changes in subjective and objective measures of driving impairment. Research is needed to objectively characterize kratom's impact on driving in regular and infrequent consumers.

Citing Articles

An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans.

Prevete E, Theunissen E, Kuypers K, Paci R, Reckweg J, Cavarra M Psychopharmacology (Berl). 2024; .

PMID: 39724441 DOI: 10.1007/s00213-024-06734-2.


Kratom safety and toxicology in the public health context: research needs to better inform regulation.

Henningfield J, Grundmann O, Huestis M, Smith K Front Pharmacol. 2024; 15:1403140.

PMID: 38887550 PMC: 11180979. DOI: 10.3389/fphar.2024.1403140.

References
1.
Obeng S, Kamble S, Reeves M, Restrepo L, Patel A, Behnke M . Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. J Med Chem. 2019; 63(1):433-439. PMC: 7676998. DOI: 10.1021/acs.jmedchem.9b01465. View

2.
Ronen A, Chassidim H, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R . The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 2010; 42(6):1855-65. DOI: 10.1016/j.aap.2010.05.006. View

3.
Swogger M, Hart E, Erowid F, Erowid E, Trabold N, Yee K . Experiences of Kratom Users: A Qualitative Analysis. J Psychoactive Drugs. 2015; 47(5):360-7. DOI: 10.1080/02791072.2015.1096434. View

4.
Grundmann O, Veltri C, Morcos S, Smith K, Singh D, Corazza O . Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey. Exp Clin Psychopharmacol. 2023; 31(5):963-977. PMC: 10336173. DOI: 10.1037/pha0000632. View

5.
Sharma A, Kamble S, Leon F, Chear N, King T, Berthold E . Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2019; 11(8):1162-1171. PMC: 7927418. DOI: 10.1002/dta.2604. View